Scholars Central

Conference abstract

Tmax evaluation in the bioequivalence studies of generic modified release proton pump inhibitors

Authors: Ping Ren, Xiaojian Jiang, Ethan, Stier, Barbara Davit

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Purpose: In bioequivalence (BE) studies submitted to Abbreviated New Drug Applications (ANDAs), AUCt, AUCinf and C max are compared statistically to determine whether two products are bioequivalent. The FDA also qualitatively evaluates T max, to determine if any pronounced differences between test (T) and reference (R) are clinically significant. The purpose of this study was to use pharmacokinetic (PK), pharmacodynamic (PD), safety, simulated steady state, and clinical evaluation to determine whether differences in T and R T max values would affect therapeutic equivalence for modified-release proton pump inhibitors (PPIs). Methods: We retrospectively collected T max data from 48 ANDAs containing total 113 BE studies including fasting, fed, and sprinkled BE studies for five modified-release PPI drug products. The T max T/R ratio distribution for each study was analyzed. For studies for which test and reference T max values appeared to be notably different, we performed simulations to predict steady- state PK profiles using nonparametric superposition. Additionally, we also conducted pair-wise statistical comparisons of the BE study adverse events (AEs) between the T and R products. We related the PK profiles in the BE studies to the known PK/ PD relationships for PPIs. Finally, the clinical impact of the most pronounced T max differences on therapeutic equivalence was evaluated by FDA medical officers with expertise in treating GI disease. Results: All studies met BE acceptance limits for AUC and C max . The distribution of the median T max T/R ratios from the 113 studies suggested that, in approximate 10% of studies, there was a possible pronounced difference in T and R T max values, primarily in the fasting studies. Simulation results indicated that differences in median R and T T max values were diminished at steady state. The distribution profile of adverse events for the test product was similar to that of the reference product. Finally, the clinical evaluation assessed PPI PK/PD and concluded that even the most pronounced T max differences were not expected to have an impact on safety and efficacy. Conclusion: Our data analysis, PK/PD relationships, and clinical evaluation indicated that any T max differences between T and R in BE studies submitted from in-house applications for generic modified-release PPI drug products were unlikely to impact therapeutic equivalence PDF HTML

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioequivalence & Bioavailability.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioequivalence & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Ping Ren”
  • BylineArticles whose byline prints “Xiaojian Jiang”
  • BylineArticles whose byline prints “Ethan”
  • BylineArticles whose byline prints “Stier”
  • BylineArticles whose byline prints “Barbara Davit”